As a member of the Executive Committee, we represent direct purchasers of Effexor XR who were prevented from purchasing less expensive, generic versions of Effexor XR because of Defendants’ alleged scheme to monopolize the market. This scheme included committing fraud to secure a patent and paying a generic competitor to delay its market entry.